SCHEMBL479335

SCHEMBL479335

CCCC(Nc1ccc(C(C)(C)N)cc1)=C1C(=O)Nc2cc(C(=O)OCC)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.46
MAPT P10636 7/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
GAA P10253 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
TSHR P16473 2/20 0.37
CETP P11597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118011 0.93 RXFP1 (0.47) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL2118793 0.93 KMT2A (0.42) RXFP1MAPTNPC1RAB9ATP53
SCHEMBL2568677 0.89 RXFP1 (0.46) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL2568681 0.89 RXFP1 (0.46) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL480515 0.88 RXFP1 (0.48) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL2119697 0.85 KMT2A (0.43) RXFP1MAPTSMN1; SMN2TP53POLB
SCHEMBL2573629 0.84 RXFP1 (0.49) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL2567564 0.84 RXFP1 (0.43) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL479333 0.84 RXFP1 (0.43) RXFP1MAPTNPC1RAB9AGAA
SCHEMBL2124322 0.84 RXFP1 (0.40) RXFP1MAPTNPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF RXFP1 2731/4885MAPT 960/4885NPC1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.